Six month assessment of low dose rituximab in the treatment of rheumatoid arthritis during coronavirus disease 2019 (COVID-19) pandemic

Durmaz Y., İlhanlı İ.

EGYPTIAN RHEUMATOLOGIST, cilt.43, sa.3, ss.253-256, 2021 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 43 Sayı: 3
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1016/j.ejr.2021.05.001
  • Dergi Adı: EGYPTIAN RHEUMATOLOGIST
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, EMBASE, Directory of Open Access Journals
  • Sayfa Sayıları: ss.253-256
  • Anahtar Kelimeler: Covid-19, Immunoglobulin levels, Rheumatoid arthritis, Rituximab, IMMUNOGLOBULIN LEVELS, EFFICACY, SAFETY, RISK, MAINTENANCE, RETREATMENT, INFECTIONS, THERAPY, TRIAL
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

Aim of the work: To evaluate the 6-month treatment responses to low dose rituximab (LDR) compared to standard dose rituximab (SDR) in rheumatoid arthritis (RA) patients whose treatments were disrupted due to the pandemic with increased disease activity and to examine the effect of LDR treatment on serum immunoglobulin (Ig) levels.